|
Item 1.
|
Financial Statements
|
ALLIED HEALTHCARE PRODUCTS, INC.
STATEMENT OF OPERATIONS
(UNAUDITED)
|
|
Three months ended
|
|
|
Nine months ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
$
|
8,316,027
|
|
|
$
|
8,466,825
|
|
|
$
|
23,691,922
|
|
|
$
|
25,082,280
|
|
Cost of sales
|
|
|
6,765,552
|
|
|
|
7,234,067
|
|
|
|
20,057,379
|
|
|
|
20,583,535
|
|
Gross profit
|
|
|
1,550,475
|
|
|
|
1,232,758
|
|
|
|
3,634,543
|
|
|
|
4,498,745
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
1,903,408
|
|
|
|
2,120,384
|
|
|
|
5,975,580
|
|
|
|
6,397,903
|
|
Loss from operations
|
|
|
(352,933
|
)
|
|
|
(887,626
|
)
|
|
|
(2,341,037
|
)
|
|
|
(1,899,158
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (income) expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
18,590
|
|
|
|
13,433
|
|
|
|
44,548
|
|
|
|
13,433
|
|
Interest income
|
|
|
(47
|
)
|
|
|
(23
|
)
|
|
|
(107
|
)
|
|
|
(249
|
)
|
Legal settlement
|
|
|
(750,000
|
)
|
|
|
-
|
|
|
|
(750,000
|
)
|
|
|
-
|
|
Other, net
|
|
|
45
|
|
|
|
1
|
|
|
|
45
|
|
|
|
238
|
|
|
|
|
(731,412
|
)
|
|
|
13,411
|
|
|
|
(705,514
|
)
|
|
|
13,422
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes
|
|
|
378,479
|
|
|
|
(901,037
|
)
|
|
|
(1,635,523
|
)
|
|
|
(1,912,580
|
)
|
Provision for income taxes
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
136,386
|
|
Net income (loss)
|
|
$
|
378,479
|
|
|
$
|
(901,037
|
)
|
|
$
|
(1,635,523
|
)
|
|
$
|
(2,048,966
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic income (loss) per share
|
|
$
|
0.09
|
|
|
$
|
(0.22
|
)
|
|
$
|
(0.41
|
)
|
|
$
|
(0.51
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted income (loss) per share
|
|
$
|
0.09
|
|
|
$
|
(0.22
|
)
|
|
$
|
(0.41
|
)
|
|
$
|
(0.51
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding - basic
|
|
|
4,013,537
|
|
|
|
4,013,537
|
|
|
|
4,013,537
|
|
|
|
4,013,537
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding - diluted
|
|
|
4,013,537
|
|
|
|
4,013,537
|
|
|
|
4,013,537
|
|
|
|
4,013,537
|
|
See accompanying Notes to Financial Statements.
ALLIED HEALTHCARE PRODUCTS, INC.
BALANCE SHEET
ASSETS
|
|
(Unaudited)
|
|
|
|
|
|
|
March 31,
|
|
|
June 30,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
135,810
|
|
|
$
|
136,112
|
|
Accounts receivable, net of allowances of $170,000
|
|
|
3,424,371
|
|
|
|
3,747,993
|
|
Inventories, net
|
|
|
7,893,445
|
|
|
|
7,830,541
|
|
Income tax receivable
|
|
|
20,298
|
|
|
|
12,178
|
|
Other current assets
|
|
|
290,271
|
|
|
|
250,605
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
11,764,195
|
|
|
|
11,977,429
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
|
4,187,281
|
|
|
|
4,823,149
|
|
Deferred income taxes
|
|
|
520,663
|
|
|
|
520,663
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
16,472,139
|
|
|
$
|
17,321,241
|
|
See accompanying Notes to Financial Statements.
(CONTINUED)
ALLIED HEALTHCARE PRODUCTS, INC.
BALANCE SHEET
(CONTINUED)
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
(Unaudited)
|
|
|
|
|
|
|
March 31,
|
|
|
June 30,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Revolving credit facility
|
|
$
|
410,735
|
|
|
$
|
-
|
|
Accounts payable
|
|
|
1,833,469
|
|
|
|
1,473,618
|
|
Other accrued liabilities
|
|
|
1,864,213
|
|
|
|
1,850,683
|
|
Total current liabilities
|
|
|
4,108,417
|
|
|
|
3,324,301
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' equity:
|
|
|
|
|
|
|
|
|
Preferred stock; $0.01 par value; 1,500,000 shares authorized; no shares issued and outstanding
|
|
|
-
|
|
|
|
-
|
|
Series A preferred stock; $0.01 par value; 200,000 shares authorized; no shares issued and outstanding
|
|
|
-
|
|
|
|
-
|
|
Common stock; $0.01 par value; 30,000,000 shares authorized; 5,213,902 shares issued at March 31, 2019 and June 30, 2018; 4,013,537 shares outstanding at March 31, 2019 and June 30, 2018
|
|
|
52,139
|
|
|
|
52,139
|
|
Additional paid-in capital
|
|
|
48,490,525
|
|
|
|
48,488,220
|
|
Accumulated deficit
|
|
|
(15,198,154
|
)
|
|
|
(13,562,631
|
)
|
Less treasury stock, at cost; 1,200,365 shares at
|
|
|
|
|
|
|
|
|
March 31, 2019 and June 30, 2018, respectively
|
|
|
(20,980,788
|
)
|
|
|
(20,980,788
|
)
|
Total stockholders' equity
|
|
|
12,363,722
|
|
|
|
13,996,940
|
|
Total liabilities and stockholders' equity
|
|
$
|
16,472,139
|
|
|
$
|
17,321,241
|
|
See accompanying Notes to Financial Statements.
ALLIED HEALTHCARE PRODUCTS, INC.
STATEMENT OF CHANGES IN STOCKHOLDER’S
EQUITY
(UNAUDITED)
|
|
Three Months Ended March 31, 2019
|
|
|
|
|
|
|
Additional
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
|
|
|
Paid-in
|
|
|
Accumulated
|
|
|
Treasury
|
|
|
|
|
|
|
Stock
|
|
|
Capital
|
|
|
Deficit
|
|
|
Stock
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2018
|
|
$
|
52,139
|
|
|
$
|
48,489,734
|
|
|
$
|
(15,576,633
|
)
|
|
$
|
(20,980,788
|
)
|
|
$
|
11,984,452
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock based compensation
|
|
|
-
|
|
|
|
791
|
|
|
|
-
|
|
|
|
-
|
|
|
|
791
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
-
|
|
|
|
-
|
|
|
|
378,479
|
|
|
|
-
|
|
|
|
378,479
|
|
Balance at March 31, 2019
|
|
$
|
52,139
|
|
|
$
|
48,490,525
|
|
|
$
|
(15,198,154
|
)
|
|
$
|
(20,980,788
|
)
|
|
$
|
12,363,722
|
|
|
|
Three Months Ended
March 31, 2018
|
|
|
|
|
|
|
Additional
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
|
|
|
Paid-in
|
|
|
Accumulated
|
|
|
Treasury
|
|
|
|
|
|
|
Stock
|
|
|
Capital
|
|
|
Deficit
|
|
|
Stock
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2017
|
|
$
|
52,139
|
|
|
$
|
48,486,743
|
|
|
$
|
(12,518,390
|
)
|
|
$
|
(20,980,788
|
)
|
|
$
|
15,039,704
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock based compensation
|
|
|
-
|
|
|
|
739
|
|
|
|
-
|
|
|
|
-
|
|
|
|
739
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
(901,037
|
)
|
|
|
-
|
|
|
|
(901,037
|
)
|
Balance at March 31, 2018
|
|
$
|
52,139
|
|
|
$
|
48,487,482
|
|
|
$
|
(13,419,427
|
)
|
|
$
|
(20,980,788
|
)
|
|
$
|
14,139,406
|
|
|
|
Nine Months Ended March 31, 2019
|
|
|
|
|
|
|
Additional
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
|
|
|
Paid-in
|
|
|
Accumulated
|
|
|
Treasury
|
|
|
|
|
|
|
Stock
|
|
|
Capital
|
|
|
Deficit
|
|
|
Stock
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at June 30, 2018
|
|
$
|
52,139
|
|
|
$
|
48,488,220
|
|
|
$
|
(13,562,631
|
)
|
|
$
|
(20,980,788
|
)
|
|
$
|
13,996,940
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock based compensation
|
|
|
-
|
|
|
|
2,305
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2,305
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,635,523
|
)
|
|
|
-
|
|
|
|
(1,635,523
|
)
|
Balance at March 31, 2019
|
|
$
|
52,139
|
|
|
$
|
48,490,525
|
|
|
$
|
(15,198,154
|
)
|
|
$
|
(20,980,788
|
)
|
|
$
|
12,363,722
|
|
|
|
Nine Months Ended March 31, 2018
|
|
|
|
|
|
|
Additional
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
|
|
|
Paid-in
|
|
|
Accumulated
|
|
|
Treasury
|
|
|
|
|
|
|
Stock
|
|
|
Capital
|
|
|
Deficit
|
|
|
Stock
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at June 30, 2017
|
|
$
|
52,139
|
|
|
$
|
48,485,390
|
|
|
$
|
(11,370,461
|
)
|
|
$
|
(20,980,788
|
)
|
|
$
|
16,186,280
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock based compensation
|
|
|
-
|
|
|
|
2,092
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2,092
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
(2,048,966
|
)
|
|
|
-
|
|
|
|
(2,048,966
|
)
|
Balance at March 31, 2018
|
|
$
|
52,139
|
|
|
$
|
48,487,482
|
|
|
$
|
(13,419,427
|
)
|
|
$
|
(20,980,788
|
)
|
|
$
|
14,139,406
|
|
See accompanying Notes to Financial Statements.
ALLIED HEALTHCARE PRODUCTS, INC.
STATEMENT OF CASH FLOWS
(UNAUDITED)
|
|
Nine months ended
|
|
|
|
March 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(1,635,523
|
)
|
|
$
|
(2,048,966
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
635,868
|
|
|
|
703,685
|
|
Stock based compensation
|
|
|
2,305
|
|
|
|
2,092
|
|
Provision for doubtful accounts and sales returns and allowances
|
|
|
20,178
|
|
|
|
(5,124
|
)
|
Deferred taxes
|
|
|
-
|
|
|
|
136,386
|
|
|
|
|
|
|
|
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
303,444
|
|
|
|
(363,509
|
)
|
Inventories
|
|
|
(62,904
|
)
|
|
|
109,399
|
|
Income tax receivable
|
|
|
(8,120
|
)
|
|
|
(9,561
|
)
|
Other current assets
|
|
|
(39,666
|
)
|
|
|
59,304
|
|
Accounts payable
|
|
|
359,851
|
|
|
|
199,544
|
|
Other accrued liabilities
|
|
|
13,530
|
|
|
|
(195,081
|
)
|
Net cash used in operating activities
|
|
|
(411,037
|
)
|
|
|
(1,411,831
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
Borrowings under revolving credit agreement
|
|
|
24,375,484
|
|
|
|
7,025,454
|
|
Payments under revolving credit agreement
|
|
|
(23,964,749
|
)
|
|
|
(6,342,682
|
)
|
Net cash provided by financing activities
|
|
|
410,735
|
|
|
|
682,772
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
(302
|
)
|
|
|
(729,059
|
)
|
Cash and cash equivalents at beginning of period
|
|
|
136,112
|
|
|
|
995,704
|
|
Cash and cash equivalents at end of period
|
|
$
|
135,810
|
|
|
$
|
266,645
|
|
See accompanying Notes to Financial Statements.
ALLIED HEALTHCARE PRODUCTS, INC.
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
1. Summary of Significant Accounting and Reporting Policies
Basis of Presentation
The accompanying unaudited
financial statements of Allied Healthcare Products, Inc. (the “Company”) have been prepared in accordance with the
instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally
accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting
only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any
quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read
in conjunction with the financial statements and notes to the financial statements thereto included in the Company’s Annual
Report on Form 10-K for the year ended June 30, 2018.
Adoption of new revenue recognition
standard
In May 2014, the Financial
Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the recognition of revenue from
contracts with customers to transfer goods and services. The FASB subsequently issued additional, clarifying standards to address
issues arising from implementation of the new revenue recognition standard. The new revenue recognition standard and clarifying
standards require an entity to recognize revenue when control of promised goods or services is transferred to the customer at an
amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The
Company adopted this new standard as of July 1, 2018, by applying the modified-retrospective method to those contracts that were
not completed as of that date.
The results for reporting
periods beginning after July 1, 2018, are presented in accordance with the new standard, although comparative information has not
been restated and continues to be reported under the accounting standards and policies in effect for those periods. See Note 2,
Summary of Significant Accounting Policies, to the financial statements in our Annual Report on Form 10-K for the year ended June
30, 2018.
The cumulative impact
on accumulated deficit as a result of the adoption of this standard did not have a material impact on the Company’s historical
net losses and, therefore, no adjustment was made to the opening balance of accumulated deficit. In addition, the impact on reported
total revenues and operating income as compared to what reported amounts would have been under the prior standard was also immaterial.
The Company expects the impact of adoption in future periods to also be immaterial. The accounting policies under the new standard
were applied prospectively and are described below. See Note 2, Revenues.
Recently Issued Accounting Guidance
In February 2016, the FASB issued ASU 2016-02,
“Leases (Topic 842)” (“ASU 2016-02”), which requires lessees to recognize assets and liabilities for leases
with lease terms of more than 12 months and disclose key information about leasing arrangements. Consistent with current U.S. GAAP,
the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend
on its classification as a finance or operating lease. The update is effective for reporting periods beginning after December 15,
2018. Early adoption is permitted. The Company is in the process of evaluating the impact of this update on its financial statements.
Fair Value of Financial Instruments
The Company’s
financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and the revolving credit facility.
The carrying amounts for cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to
the short maturity of these instruments. The carrying amount of the revolving credit facility approximates fair value due to the
debt having a variable interest rate.
2. Revenues
The Company’s
revenues are derived primarily from the sales of respiratory products, medical gas equipment and emergency medical products. The
products are generally sold directly to distributors, customers affiliated with buying groups, individual customers and construction
contractors, throughout the world.
The Company recognizes
revenue from product sales upon the transfer of control, which is generally upon shipment or delivery, depending on the delivery
terms set forth in the customer contract. Payment terms between Allied and its customers vary by the type of customer, country
of sale, and the products offered. The term between invoicing and the payment due date is not significant.
Management exercises
judgment in estimating variable consideration. Provisions for early payment discounts, rebates and returns and other adjustments
are provided for in the period the related sales are recorded. Historical data is readily available and reliable, and is used for
estimating the amount of the reduction in gross sales.
The Company provides
rebates to wholesalers. Rebate amounts are based upon purchases using contractual amount for each product sold. Factors used in
the rebate calculations include the identification of which products have been sold subject to a rebate and the customer or price
terms that apply. Using known contractual allowances, the Company estimates the amount of the rebate that will be paid, and records
the liability as a reduction of gross sales when it records the sale of the product. Settlement of the rebate generally occurs
in the month following the sale.
The Company regularly
analyzes the historical rebate trends and makes adjustments to reserves for changes in trends and terms of rebate programs. Historically,
adjustments to prior years’ rebate accruals have not been material to net income.
Other allowances charged
against gross sales include cash discounts and returns, which are not significant. Cash discounts are known within 15 to 30 days
of sale, and therefore can be reliably estimated. Returns can be reliably estimated because the Company’s historical returns
are low, and because sales return terms and other sales terms have remained relatively unchanged for several periods. Product warranties
are also not significant.
The Company does not allocate transaction
price as the Company has only one performance obligation and its contracts do not span multiple periods.
The
Company operates in one segment consisting of the
manufacturing, marketing and distribution of a variety of respiratory
products used in the health care industry to hospitals, hospital equipment dealers, hospital construction contractors, home health
care dealers and emergency medical product dealers. The Company’s product lines include respiratory care products, medical
gas equipment and emergency medical products.
The Company does not have
any one single customer that represents more than 10 percent of total sales. Sales by region, and by product, are as follows:
|
|
Sales by Region
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
|
Nine months ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Domestic United States
|
|
$
|
6,128,063
|
|
|
$
|
6,786,536
|
|
|
$
|
17,819,577
|
|
|
$
|
19,171,616
|
|
Europe
|
|
|
327,357
|
|
|
|
346,449
|
|
|
|
707,296
|
|
|
|
1,094,175
|
|
Canada
|
|
|
212,219
|
|
|
|
191,511
|
|
|
|
585,542
|
|
|
|
556,133
|
|
Latin America
|
|
|
515,753
|
|
|
|
350,890
|
|
|
|
1,642,390
|
|
|
|
1,393,095
|
|
Middle East
|
|
|
236,834
|
|
|
|
180,111
|
|
|
|
382,845
|
|
|
|
724,825
|
|
Far East
|
|
|
892,044
|
|
|
|
608,931
|
|
|
|
2,534,292
|
|
|
|
2,138,106
|
|
Other International
|
|
|
3,757
|
|
|
|
2,397
|
|
|
|
19,980
|
|
|
|
4,330
|
|
|
|
$
|
8,316,027
|
|
|
$
|
8,466,825
|
|
|
$
|
23,691,922
|
|
|
$
|
25,082,280
|
|
|
|
Sales by Product
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
|
Nine months ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory care products
|
|
$
|
2,292,547
|
|
|
$
|
2,225,975
|
|
|
$
|
6,707,384
|
|
|
$
|
6,534,769
|
|
Medical gas equipment
|
|
|
4,371,944
|
|
|
|
4,613,990
|
|
|
|
12,191,622
|
|
|
|
13,281,247
|
|
Emergency medical products
|
|
|
1,651,536
|
|
|
|
1,626,860
|
|
|
|
4,792,916
|
|
|
|
5,266,264
|
|
|
|
$
|
8,316,027
|
|
|
$
|
8,466,825
|
|
|
$
|
23,691,922
|
|
|
$
|
25,082,280
|
|
3. Inventories
Inventories are comprised as follows:
|
|
March 31, 2019
|
|
|
June 30, 2018
|
|
|
|
|
|
|
|
|
Work-in progress
|
|
$
|
519,288
|
|
|
$
|
388,252
|
|
Component parts
|
|
|
7,040,549
|
|
|
|
6,775,870
|
|
Finished goods
|
|
|
1,953,025
|
|
|
|
2,285,836
|
|
Reserve for obsolete and excess
|
|
|
|
|
|
|
|
|
inventories
|
|
|
(1,619,417
|
)
|
|
|
(1,619,417
|
)
|
|
|
$
|
7,893,445
|
|
|
$
|
7,830,541
|
|
4. Earnings per share
Basic earnings per
share are based on the weighted average number of shares of all common stock outstanding during the period. Diluted earnings per
share are based on the sum of the weighted average number of shares of common stock and common stock equivalents outstanding during
the period. The number of basic and diluted shares outstanding for the three and nine months ended March 31, 2019 and 2018 were
4,013,537.
5. Commitments and Contingencies
Legal Claims
The Company is subject
to various investigations, claims and legal proceedings covering a wide range of matters that arise in the ordinary course of its
business activities. The Company intends to continue to conduct business in such a manner as to avert any FDA action seeking to
interrupt or suspend manufacturing or require any recall or modification of products.
The Company has recognized
the costs and associated liabilities only for those investigations, claims and legal proceedings for which, in its view, it is
probable that liabilities have been incurred and the related amounts are estimable. Based upon information currently available,
management believes that existing accrued liabilities are sufficient.
Stuyvesant Falls
Power Litigation
. The Company has been involved in litigation with Niagara Mohawk Power Corporation d/b/a National Grid (“Niagara”),
which provides electrical power to the Company’s facility in Stuyvesant Falls, New York, and one other party. The Company
maintained in its defense of the lawsuit that it is entitled to a certain amount of free electricity based on covenants running
with the land which have been honored for more than a century. After the commencement of the litigation, Niagara began sending
invoices to the Company for electricity used at the Company’s Stuyvesant Falls plant. Niagara’s attempts to collect
such invoices were stopped in December 2010 by a temporary restraining order. Among other things, Niagara sought as damages the
value of electricity received by the Company without charge. The total value of electricity at issue in the litigation was not known
with certainty and Niagara alleged different amounts of damages. Niagara alleged in its Second Amended Verified Complaint,
dated February 6, 2012, damages of approximately $469,000 in free electricity from May 2003 through May 2010. Niagara also alleged
in its Motion For Summary Judgment, filed on March 14, 2014, damages of approximately $492,000 in free electricity from May 2010
through the date of the filing. In April 2015, Allied received an invoice for electrical power at the Stuyvesant Falls plant with
an “Amount Due” balance of $696,000 as of March 31, 2015 without any description as to the period of time covered by
the invoice.
The Company filed a
Motion for Summary Judgment on March 14, 2014, seeking dismissal of Niagara’s claims and oral arguments on the motions were
held on June 13, 2014. On October 1, 2014, the Court granted the Company’s motion, denied Niagara’s motion and ruled
that the Company is entitled to receive electrical power pursuant to the power covenants. On October 26 and October 30, 2014, Niagara
and the other party filed separate notices of appeal of the Court’s decision. On March 31, 2016 the Supreme Court of New
York, Appellate Division, Third Department reversed the trial court decision and held that the free power covenants are no longer
enforceable. The Company’s application for leave to appeal this ruling was dismissed as premature by the New York Court of
Appeals on September 20, 2016. On May 26, 2017 the Company again moved for leave to appeal the March 31, 2016 decision. That motion
was granted on October 7, 2017 by the New York State Court of Appeals. The Company filed its brief and record on January 26, 2018.
Niagara and the other party to the lawsuit, Albany Engineering Corporation, filed their responses on July 16, 2018 and the Company
filed its reply on August 14, 2018.
On February 20, 2019,
the Company, Niagara and Albany entered into a Final Settlement Agreement pursuant to which the Company agreed, among other things,
to cancel and forgo its rights to free power from either Niagara or Albany under the power covenants. The New York State Court
of Appeals granted a request of all parties to withdraw the appeal on March 5, 2019 and all parties entered a Stipulation of Discontinuance
on March 7, 2019 which discontinued the litigation. By separate agreement, Niagara paid the Company $750,000 as consideration for
the Company’s agreements pursuant to the settlement. On March 15, 2019 the Appellate Division of the Supreme Court of New
York granted Niagara’s request to withdraw its pending appeal. The matter is now fully concluded.
Employment Contract
The Company has entered
into an employment contract with its chief executive officer with annual renewals. The contract includes termination without cause
and change of control provisions, under which the chief executive officer is entitled to receive specified severance payments generally
equal to two times ending annual salary if the Company terminates his employment without cause or he voluntarily terminates his
employment with “good reason.” “Good Reason” generally includes changes in the scope of his duties or location
of employment but also includes (i) the Company’s written election not to renew the Employment Agreement and (ii) certain
voluntary resignations by the chief executive officer following a “Change of Control” as defined in the Agreement.
6. Financing
The Company is party
to a Loan and Security Agreement with Summit Financial Resources, L.P. (“Summit”), dated effective February 27, 2017,
as amended April 16, 2018 and April 24, 2019 (as amended, the “Credit Agreement”). Pursuant to the Credit Agreement,
the Company obtained a secured revolving credit facility (the “Credit Facility”). The Company’s obligations under
the Credit Facility are secured by all of the Company’s personal property, both tangible and intangible, pursuant to the
terms and subject to the conditions set forth in the Credit Agreement. Availability of funds under the Credit Agreement is based
on the Company’s accounts receivable and inventory but will not exceed $2,000,000. At March 31, 2019 availability under
the agreement was $1,502,130.
The Credit Facility
will be available, subject to its terms, on a revolving basis until it expires on February 27, 2021, at which time all amounts
outstanding under the Credit Facility will be due and payable. Advances will bear interest at a rate equal to 2.00% in excess of
the prime rate as reported in the Wall Street Journal. Interest is computed based on the actual number of days elapsed over a year
of 360 days. In addition to interest, the Credit facility requires that the Company pay the lender a monthly administration fee
in an amount equal to forty-seven hundredths percent (0.47%) of the average outstanding daily principal amount of loan advances
for the each calendar month, or portion thereof.
Regardless of the
amount borrowed under the Credit Facility, the Company will pay a minimum amount of .25% (25 basis points) per month on the maximum
availability ($5,000 per month). In the event the Company prepays or terminates the Credit Facility prior to February 27, 2021,
the Company will be obligated to pay an amount equal to the minimum monthly payment multiplied by the number of months remaining
between February 27, 2021 and the date of such prepayment or termination.
Under the Credit Agreement,
advances are generally subject to customary borrowing conditions and to Summit’s sole discretion to fund the advances. The
Credit Agreement also contains covenants with which the Company must comply during the term of the Credit Facility. Among other
things, such covenants require the Company to maintain insurance on the collateral, operate in the ordinary course and not engage
in a change of control, dissolve or wind up the Company.
The Credit Agreement
also contains certain events of default including, without limitation: the failure to make payments when due; the material breach
of representations or warranties contained in the Credit Agreement or other loan documents; cross-default with other indebtedness
of the Company; the entry of judgments or fines that may have a material adverse effect on the Company; failure to comply with
the observance or performance of covenants contained in the Credit Agreement or other loan documents; insolvency of the Company,
appointment of a receiver, commencement of bankruptcy or other insolvency proceedings; dissolution of the Company; the attachment
of any state or federal tax lien; attachment or levy upon or seizure of the Company’s property; or any change in the Company’s
condition that may have a material adverse effect. After an event of default, and upon the continuation thereof, the principal
amount of all loans made under the Credit Facility would bear interest at a rate per annum equal to 20.00% above the otherwise
applicable interest rate (provided, that the interest rate may not exceed the highest rate permissible under law), and Summit would
have the option to accelerate maturity and payment of the Company’s obligations under the Credit Facility.
At March 31, 2019, the Company had $410,735
of indebtedness, including capital lease obligations, short-term debt and long term debt. The prime rate as reported in the Wall
Street Journal was 5.50% on March 31, 2019.
The Company was in
compliance with all of the covenants associated with the Credit Facility at March 31, 2019.
7. Income Taxes
The Company accounts
for income taxes under ASC Topic 740: “Income Taxes.” Under ASC 740, the deferred tax provision is determined using
the liability method, whereby deferred tax assets and liabilities are recognized based upon temporary differences between the financial
statement and income tax bases of assets and liabilities using presently enacted tax rates. Valuation allowances are established
when necessary to reduce deferred tax assets to the amounts expected to be realized. Due to the reduction in the cumulative to
date loss occurring in the three months ended March 31, 2019, the Company recorded a provision for income taxes of approximately
$100,000 along with a reduction in the valuation allowance for a like amount. For the nine months ended March 31, 2019 the Company
recorded the tax benefit of cumulative losses incurred to date in the amount of approximately $406,000. As the realization of the
tax benefit of the net operating loss incurred to date is not assured an additional valuation allowance of a like amount was recorded.
For the three and nine
months ended March 31, 2018 the Company recorded the tax benefit of losses incurred in the amount of approximately $260,000 and
$627,000. As the realization of the tax benefit of the net operating loss is not assured an additional valuation allowance of a
like amount was recorded. The total valuation allowance recorded by the Company as of March 31, 2019 and 2018 was approximately
$2,606,000 and $2,132,000, respectively.
The Tax Cuts and Jobs
Act (“TCJA”) was enacted in the U.S. on December 22, 2017. The TCJA reduced the U.S. federal corporate tax rate from
35% to 21%. As a result of this reduction in rate in the second quarter of the fiscal year ended 2018 the Company recorded a reduction
in its recognized deferred tax assets along with a reduction in the valuation allowance. The impact of those adjustments resulted
in a net reduction of recognized deferred tax assets and a resultant income tax expense in the amount of $136,386 for the nine-months
ended March 31, 2018. To the extent that the Company’s losses continue in future quarters, the tax benefit of those losses
will be subject to a valuation allowance.
Item 2. Management’s Discussion and Analysis of Financial
Condition and Results of Operations
Results of Operations
Three months ended March 31, 2019 compared to three months
ended March 31, 2018
Allied had net sales
of $8.3 million for the three months ended March 31, 2019, down $0.2 million from net sales of $8.5 million in the prior year same
quarter. Domestic sales were down 9.7% while international sales, which represented 26.3% of third quarter sales, were up 30.2%
from the prior year same quarter.
Orders for the Company’s
products for the three months ended March 31, 2019 of $7.9 million were $0.9 million or 10.2% lower than orders for the prior year
same quarter of $8.8 million. Domestic orders are down 16.9% over the prior year same quarter, primarily construction products,
while international orders, which represented 29.7% of third quarter orders, were 10.8% higher than orders for the prior year same
quarter. International sales and orders are subject to fluctuation in international demand. International sales can be impacted
by political and economic uncertainty in regions and countries where the Company markets its products.
Gross profit for the
three months ended March 31, 2019 was $1.6 million, or 19.3% of net sales, compared to $1.2 million, or 14.1% of net sales, for
the three months ended March 31, 2018. The $0.4 million increase in gross profit is partially due to lower fixed manufacturing
cost including a $133,000 decrease in fringe benefits, a $35,000 decrease in manufacturing salaries, and a $70,000 decrease in
net product warranty and repair cost. In addition, margins improved due to a $26,000 reduction in scrap expense, higher utilization
of fixed manufacturing cost and favorable changes in product mix.
Selling, general and
administrative expenses for the three months ended March 31, 2019 were $1.9 million compared to $2.1 million for the three months
ended March 31, 2018. Personnel cost, primarily salary and fringe benefits, decreased by approximately $74,000. Legal expenses
and business taxes are approximately $76,000 lower than in the prior year. Travel expense was $28,000 lower than in the prior year.
Loss from operations
was $352,933 for the three months ended March 31, 2019 compared to $887,626 for the three months ended March 31, 2018.
Other income and expenses
for the three months ended March 31, 2019 include approximately $750,000 of income realized by the Company as a result of the settlement
of litigation with Niagara Mohawk Power Corporation d/b/a National Grid (“Niagara”), which provides electrical power
to the Company’s facility in Stuyvesant Falls, New York, and one other party. See Part II, Item 1 – Legal Proceedings,
below, for more information concerning litigation. Interest expense for the three months ended March 31, 2019 was approximately
$19,000 compared to interest expense of $13,000 for the three months ended March 31, 2018.
Allied had income before
provision for income taxes in the third quarter of fiscal 2019 of $378,479 compared to loss before benefit from income taxes in
the third quarter of fiscal 2018 of $901,037. The Company’s tax provision net of valuation allowance reflects a tax benefit
of $0 for the three months ended March 31, 2019 and 2018. Due to the reduction in the cumulative to date loss occurring in the
three months ended March 31, 2019, a tax provision in the amount of $100,000 was recorded offset by a reduction in the valuation
allowance. In the quarter ended March 31, 2018, the tax benefit of loss incurred in the quarter in the amount of $260,000, was
recorded and fully offset by a valuation allowance of equivalent amount. To the extent that the Company’s losses continue
in future quarters, the tax benefit of those losses will be fully offset by a valuation allowance.
Net income for the
third quarter of fiscal 2019 was $378,479 or $0.09 per basic and diluted share compared to net loss of $901,037 or $0.22 per basic
and diluted share for the third quarter of fiscal 2018. The weighted average number of common shares outstanding, used in the calculation
of basic and diluted earnings per share for the third quarters of fiscal 2019 and 2018 were 4,013,537.
Nine months ended March 31, 2019 compared to nine months
ended March 31, 2018
Allied had net sales
of $23.7 million for the nine months ended March 31, 2019, down $1.4 million, or 5.6% from net sales of $25.1 million in the prior
year same period resulting from lower order levels and a decrease in customer orders released for shipment. Domestic sales were
down 7.1% from the prior year same period while international sales were down 0.6% from the prior year same period. International
represented 24.8% of sales for the first nine months of fiscal 2019 business.
Orders for the Company’s
products for the nine months ended March 31, 2019 of $23.2 million were $1.3 million or 5.3% lower than orders for the prior year
same period of $24.5 million. Domestic orders are down 10.8% from the prior year same period while international orders, which
represented 27.8% of orders for the first nine months of fiscal 2019, were 13.7% higher than orders for the prior year same period.
The level of domestic orders reflects variability across product lines, however the decrease in orders for the first nine months
were concentrated in domestic construction products. The international market and the market in domestic construction products
do reflect variability across periods. The Company continues to work to improve the sales effort in construction with increased
management reporting on sales activity and effectiveness.
Gross profit for the
nine months ended March 31, 2019 was $3.6 million, or 15.2% of net sales, compared to $4.5 million, or 17.9% of net sales, for
the nine months ended March 31, 2018. The $0.9 million decrease in gross profit is mostly attributable to the $1.4 million decrease
in sales. Lower sales and lower production resulted in less utilization of fixed overhead expenses.
Selling, general and
administrative expenses for the nine months ended March 31, 2019 were $6.0 million compared to $6.4 million for the nine months
ended March 31, 2018. Salaries and benefits are approximately $0.1 million lower than in the prior year, legal expenses were approximately
$0.1 million lower and business travel approximately $0.1 million lower.
Loss from operations
was $2.3 million for the nine months ended March 31, 2019 compared to $1.9 million for the nine months ended March 31, 2018.
Other income and expenses
for the nine months ended March 31, 2019 include approximately $750,000 of income realized by the Company as a result of the settlement
of litigation with Niagara Mohawk Power Corporation d/b/a National Grid (“Niagara”), which provides electrical power
to the Company’s facility in Stuyvesant Falls, New York, and one other party. See Part II, Item 1 – Legal Proceedings,
below, for more information concerning litigation. Interest expense for the nine months ended March 31, 2019 was approximately
$45,000 compared to interest expense of $13,000 for the nine months ended March 31, 2018.
Allied had a loss before
provision for income taxes in the first nine months of fiscal 2019 of $1.6 million compared to loss before provision for income
taxes in the third quarter of fiscal 2018 of $1.9 million. The Company’s tax provision net of valuation allowance reflects
a tax provision of $0 and $136,386 for the nine months ended March 31, 2019 and 2018. In the nine months ended March 31, 2018,
the Company revaluated its deferred tax assets, liabilities and valuation allowance to reflect the changes in tax rate occurring
in connection with the TCJA. The impact of the revaluation was a current period provision for income taxes in 2018 in the amount
of $136,386. In the nine months ended March 31, 2019 and 2018, the tax benefit of losses in the amount of approximately $406,000
and $627,000, respectively were fully offset by a valuation allowance of an equivalent amount. To the extent that the Company’s
losses continue in future quarters, the tax benefit of those losses will be fully offset by a valuation allowance.
Net loss for the nine
months ended March 31, 2019 was $1.6 million or $0.41 per basic and diluted share compared to net loss of $2.0 million or $0.51
per basic and diluted share for the first nine months of fiscal 2018. The weighted average number of common shares outstanding,
used in the calculation of basic and diluted earnings per share for the first nine months of fiscal 2019 and 2018 was 4,013,537.
Liquidity and Capital Resources
The Company’s
primary sources of liquidity are its cash, cash equivalents, other items of working capital and available borrowing under the Credit
Facility discussed below.
The Company’s
working capital was $7.7 million at March 31, 2019 compared to $8.7 million at June 30, 2018. Accounts Receivable decreased by
$0.3 million, Accounts Payable increased by $0.4 million and debt increased $0.4 million. During fiscal 2019, these decreases in
working capital were partially offset by a $0.1 million increase in Inventory. Accounts Payable and Other Accrued Liabilities are
subject to normal fluctuations in purchasing levels and the timing of payments within the quarter. Accounts Receivable was $3.4
million at March 31, 2019, a decrease from $3.7 million at June 30, 2018. Accounts Receivable as measured in days sales outstanding
(“DSO”) was 39 DSO at March 31, 2019; a decrease from 41 DSO at June 30, 2018. The Company does adjust product forecast,
order quantities and safety stock based on changes in demand patterns in order to manage inventory levels.
As of March 31, 2019,
the Company was party to a Loan and Security Agreement with Summit Financial Resources, L.P. (“Summit”), dated effective
February 27, 2017, as amended April 16, 2018 and April 24, 2019 (as amended, the “Credit Agreement”). Pursuant to the
Credit Agreement, the Company obtained a secured revolving credit facility (the “Credit Facility”). The Company’s
obligations under the Credit Facility are secured by all of the Company’s personal property, both tangible and intangible,
pursuant to the terms and subject to the conditions set forth in the Credit Agreement. Availability of funds under the Credit Agreement
is based on the Company’s accounts receivable and inventory but will not exceed $2,000,000. At March 31, 2019 availability
under the agreement was $1,502,130. The increase in availability during the quarter reflects decreased borrowing due to improved
cash flow in the quarter. The Company expects that it will use the Credit Facility to finance the Company’s operations in
the short term.
The Credit Facility
will be available, subject to its terms, on a revolving basis until it expires on February 27, 2021, at which time all amounts
outstanding under the Credit Facility will be due and payable. Advances will bear interest at a rate equal to 2.00% in excess of
the prime rate as reported in the Wall Street Journal. Interest is computed based on the actual number of days elapsed over a year
of 360 days. In addition to interest, the Credit facility requires that the Company pay the lender a monthly administration fee
in an amount equal to forty-seven hundredths percent (0.47%) of the average outstanding daily principal amount of loan advances
for the each calendar month, or portion thereof.
Regardless of the
amount borrowed under the Credit Facility, the Company will pay a minimum amount of .25% (25 basis points) per month on the maximum
availability ($5,000 per month). In the event the Company prepays or terminates the Credit Facility prior to February 27, 2021,
the Company will be obligated to pay an amount equal to the minimum monthly payment multiplied by the number of months remaining
between February 27, 2021 and the date of such prepayment or termination.
Under the Credit Agreement,
advances are generally subject to customary borrowing conditions and to Summit’s sole discretion to fund the advances. The
Credit Agreement also contains covenants with which the Company must comply during the term of the Credit Facility. Among other
things, such covenants require the Company to maintain insurance on the collateral, operate in the ordinary course and not engage
in a change of control, dissolve or wind up the Company.
The Credit Agreement
also contains certain events of default including, without limitation: the failure to make payments when due; the material breach
of representations or warranties contained in the Credit Agreement or other loan documents; cross-default with other indebtedness
of the Company; the entry of judgments or fines that may have a material adverse effect on the Company; failure to comply with
the observance or performance of covenants contained in the Credit Agreement or other loan documents; insolvency of the Company,
appointment of a receiver, commencement of bankruptcy or other insolvency proceedings; dissolution of the Company; the attachment
of any state or federal tax lien; attachment or levy upon or seizure of the Company’s property; or any change in the Company’s
condition that may have a material adverse effect. After an event of default, and upon the continuation thereof, the principal
amount of all loans made under the Credit Facility would bear interest at a rate per annum equal to 20.00% above the otherwise
applicable interest rate (provided, that the interest rate may not exceed the highest rate permissible under law), and Summit would
have the option to accelerate maturity and payment of the Company’s obligations under the Credit Facility.
At March 31, 2019,
the Company had $410,735 of indebtedness, including capital lease obligations, short-term debt, and long term debt. The prime rate
as reported in the Wall Street Journal was 5.50% on March 31, 2019.
Further reductions
in availability, either due to continued losses or changes by Summit to the Company’s borrowing base, could have a material
adverse impact on our liquidity and ability to meet our operating requirements. In such a case, the Company would need to access
additional sources of liquidity if it does not return to profitability. If the Company were unable to reach such an agreement with
Summit to increase availability, the Company could also attempt to negotiate a larger credit facility with another lender, but
the Company would be obligated to pay the above described pre-payment penalty to Summit. There is no assurance that the Company
could secure either increased availability from Summit or a new credit facility from a new lender, in which case the Company would
have to use other assets to obtain liquidity, such as a sale-leaseback of some or all of its real estate.
The
Company was in compliance with all of the covenants associated with the Credit Facility at March 31, 2019.
Litigation and Contingencies
The
Company becomes, from time to time, a party to personal injury litigation arising out of incidents involving the use of its products.
The Company believes that any potential judgments resulting from these claims over its self-insured retention will be covered by
the Company’s product liability insurance. See Part II, Item 1 – Legal Proceedings, below, for more information concerning
litigation.
Critical Accounting Policies
The impact and any
associated risks related to the Company’s critical accounting policies on business operations are discussed throughout “Management’s
Discussion and Analysis of Financial Condition and Results of Operations,” where such policies affect the Company’s
reported and expected financial results. For a detailed discussion on the application of these and other accounting policies, see
the Company’s Annual Report on Form 10-K for the year ended June 30, 2018.
Recently Issued Accounting Guidance
See Note 1 –
Summary of Significant Accounting and Reporting Policies for more information on recent accounting pronouncements and their impact,
if any, on the Company’s financial statements. Management believes there have been no material changes to our critical accounting
policies.